Activable Multi-Modal Nanoprobes for Imaging Diagnosis and Therapy of Tumors

Yang, Yan; Yue, Saisai; Qiao, Yuanyuan; Zhang, Peisen; Jiang, Ni; Ning, Zhenbo; Liu, Chunyan; Hou, Yi

doi:10.3389/fchem.2020.572471

Cited by 11 publications

(6 citation statements)

References 175 publications

(159 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The characteristics of the tumor microenvironment play a major role in determining the success of cancer immunotherapies. 58 , 59 It is known that solid tumors can progressively develop several specific pathways to evade immune clearance, including through a microenvironmental remodeling process known as “cancer immunoediting”. This process imposes selective pressures within the tumor microenvironment, promoting the aggravation of cancer.…”

Section: Reversing the Immune Status Of The Primary Tumormentioning

confidence: 99%

Nanotechnology-enhanced immunotherapy for metastatic cancer

Zhang

Meng

et al. 2021

The Innovation

Self Cite

View full text Add to dashboard Cite

A vast majority of cancer deaths occur as a result of metastasis. Unfortunately, effective treatments for metastases are currently lacking due to the difficulty of selectively targeting these small, delocalized tumors distributed across a variety of organs. However, nanotechnology holds tremendous promise for improving immunotherapeutic outcomes in patients with metastatic cancer. In contrast to conventional cancer immunotherapies, rationally designed nanomaterials can trigger specific tumoricidal effects, thereby improving immune cell access to major sites of metastasis such as bone, lungs, and lymph nodes, optimizing antigen presentation, and inducing a persistent immune response. This paper reviews the cutting-edge trends in nano-immunoengineering for metastatic cancers with an emphasis on different nano-immunotherapeutic strategies. Specifically, it discusses directly reversing the immunological status of the primary tumor, harnessing the potential of peripheral immune cells, preventing the formation of a pre-metastatic niche, and inhibiting the tumor recurrence through postoperative immunotherapy. Finally, we describe the challenges facing the integration of nanoscale immunomodulators and provide a forward-looking perspective on the innovative nanotechnology-based tools that may ultimately prove effective at eradicating metastatic diseases.

show abstract

Section: Reversing the Immune Status Of The Primary Tumormentioning

confidence: 99%

Nanotechnology-enhanced immunotherapy for metastatic cancer

Zhang

Meng

et al. 2021

The Innovation

Self Cite

View full text Add to dashboard Cite

show abstract

“…To address this issue, the concept of stimulus-responsive nanomaterials has been proposed. Such nanomaterials can be activated to exhibit therapeutic efficacy only in the tumor tissues under the stimulation of specific tumor pathological hallmarks, while remaining "silent" in normal tissues to ensure biosafety features [25][26][27][28][29]. For example, in our previous studies, a type of nanoprobes have been developed, which can specifically target the triple-negative breast cancer, be triggered by the acidic microenvironment, and responsively release the Fe 3+ only in tumor tissues to realize a safer tumor treatment [30].…”

Section: Introductionmentioning

confidence: 99%

Dual-stimuli responsive smart nanoprobe for precise diagnosis and synergistic multi-modalities therapy of superficial squamous cell carcinoma

et al. 2023

Self Cite

View full text Add to dashboard Cite

Background Although the promising advancements of current therapeutic approaches is available for the squamous cell carcinoma (SCC) patients, the clinical treatment of SCC still faces many difficulties. The surgical irreparable disfigurement and the postoperative wound infection largely hamper the recovery, and the chemo/radiotherapy leads to toxic side effects. Results Herein, a novel pH/Hyaluronidase (HAase) dual-stimuli triggered smart nanoprobe FeIIITA@HA has been designed through the biomineralization of Fe3+ and polyphenol tannic acid (TA) under the control of hyaluronic acid (HA) matrix. With the HA residues on the outer surface, FeIIITA@HA nanoprobes can specifically target the SCC cells through the over-expressed CD44, and accumulate in the carcinoma region after intravenously administration. The abundant HAase in carcinoma microenvironment will trigger the degradation of HA molecules, thereby exposing the FeIIITA complex. After ingesting by tumor cells via CD44 mediated endocytosis, the acidic lysosomal condition will further trigger the protonation of TA molecules, finally leading to the Fe3+ release of nanoprobe, and inducing a hybrid ferroptosis/apoptosis of tumor cells through peroxidase activity and glutathione depletion. In addition, Owing to the outstanding T1 magnetic resonance imaging (MRI) performance and phototermal conversion efficiency of nanoprobes, the MRI-guided photothermal therapy (PTT) can be also combined to complement the Fe3+-induced cancer therapy. Meanwhile, it was also found that the nanoprobes can promote the recruitment of CD4+ and CD8+ T cells to inhibit the tumor growth through the cytokines secretion. In addition, the FeIIITA@HA nanoprobes can be eliminated from the body and no obvious adverse side effect can be found in histological analysis, which confirmed the biosafety of them. Conclusion The current FeIIITA@HA nanoprobe has huge potential in clinical translation in the field of precise diagnosis and intelligent synergistic therapy of superficial SCC. This strategy will promisingly avoid the surgical defects, and reduce the systemic side effect of traditional chemotherapy, paving a new way for the future SCC treatment. Graphical Abstract

show abstract

“…[ 3 ] The malignant behaviours of tumour cells have been demonstrated to be associated with a series of molecular events inside tumour cells or in the tumour microenvironment, [ 4 ] therefore, identifying the abnormal expression of malignant pathological molecules is not only related to diagnosis and prognosis, but also has significance for therapeutic administration of cancer. [ 5 ] In previous studies and clinically statistical analyses of cancer, some key characteristics that closely related to the malignancy of tumour have been demonstrated, that is, acidic tumour microenvironment, abnormal secretion of various proteases such as hyaluronidase (HAase) and matrix metalloproteinases (MMPs), excessive glutathione (GSH), hypoxia, and abnormal redox state etc. [ 6 ] Nevertheless, most solid tumours display considerable complexity in vivo, leading to both spatial and temporal heterogeneity, which cannot be simply mimicked in vitro.…”

Section: Introductionmentioning

confidence: 99%

Molecular imaging of tumour‐associated pathological biomarkers with smart nanoprobe: From “Seeing” to “Measuring”

Zhang,

Li,

Liu

et al. 2023

Exploration

Self Cite

View full text Add to dashboard Cite

Although the extraordinary progress has been made in molecular biology, the prevention of cancer remains arduous. Most solid tumours exhibit both spatial and temporal heterogeneity, which is difficult to be mimicked in vitro. Additionally, the complex biochemical and immune features of tumour microenvironment significantly affect the tumour development. Molecular imaging aims at the exploitation of tumour‐associated molecules as specific targets of customized molecular probe, thereby generating image contrast of tumour markers, and offering opportunities to non‐invasively evaluate the pathological characteristics of tumours in vivo. Particularly, there are no “standard markers” as control in clinical imaging diagnosis of individuals, so the tumour pathological characteristics‐responsive nanoprobe‐based quantitative molecular imaging, which is able to visualize and determine the accurate content values of heterogeneous distribution of pathological molecules in solid tumours, can provide criteria for cancer diagnosis. In this context, a variety of “smart” quantitative molecular imaging nanoprobes have been designed, in order to provide feasible approaches to quantitatively visualize the tumour‐associated pathological molecules in vivo. This review summarizes the recent achievements in the designs of these nanoprobes, and highlights the state‐of‐the‐art technologies in quantitative imaging of tumour‐associated pathological molecules.

show abstract

Activable Multi-Modal Nanoprobes for Imaging Diagnosis and Therapy of Tumors

Cited by 11 publications

References 175 publications

Nanotechnology-enhanced immunotherapy for metastatic cancer

Nanotechnology-enhanced immunotherapy for metastatic cancer

Dual-stimuli responsive smart nanoprobe for precise diagnosis and synergistic multi-modalities therapy of superficial squamous cell carcinoma

Molecular imaging of tumour‐associated pathological biomarkers with smart nanoprobe: From “Seeing” to “Measuring”

Contact Info

Product

Resources

About